Table 4.

Summary of site of first recurrence.

Patients, n (%)	Cohort A (ddAC ➝ TPH) n = 199	Cohort B (FEC ➝ DPH) n = 198
Patients with a recurrence	15 (7.5)	25 (12.6)
Local recurrence	2 (1.0)	4 (2.0)
Ipsilateral after previous lumpectomy	0	2 (1.0)
Ipsilateral after previous mastectomy	1 (0.5)	2 (1.0)
Regional recurrence	2 (1.0)	4 (2.0)
Ipsilateral internal mammary lymph nodes	0	2 (1.0)
Ipsilateral axillary lymph nodes	2 (1.0)	2 (1.0)
Ipsilateral supraclavicular lymph nodes	0	1 (0.5)
Distant recurrence	13 (6.5)	13 (6.6)
Skin, subcutaneous tissue, and lymph nodes	3 (1.5)	2 (1.0)
Bone	4 (2.0)	1 (0.5)
Lung	1 (0.5)	3 (1.5)
Liver	1 (0.5)	1 (0.5)
CNS	4 (2.0)	7 (3.5)
Other	2 (1.0)	0
Second primary invasive breast cancer	2 (1.0)	2 (1.0)
Right	2 (1.0)	0
Left	0	2 (1.0)
Second primary malignancy (nonbreast)	1 (0.5)	6 (3.0)
Lung cancer	0	1 (0.5)
Colon cancer	0	2 (1.0)
Non-Hodgkin’s lymphoma	0	1 (0.5)
Other	1 (0.5)	2 (1.0)

Patients may be counted in more than one type of breast cancer recurrence category. Similarly, within breast cancer recurrence categories, patients may be counted under multiple sites/locations. CNS, central nervous system; ddAC, dose-dense doxorubicin plus cyclophosphamide; DPH, docetaxel, pertuzumab, and trastuzumab; FEC, fluorouracil, epirubicin, and cyclophosphamide; TPH, paclitaxel, pertuzumab, and trastuzumab.